N. Alejandro (Alex) Barbagelata

Journal Article Heart Lung · 2026 BACKGROUND: Cardiac myosin activators (CMAs) have been explored as a potential therapy to enhance cardiac contractility in patients with heart failure with reduced ejection fraction (HFrEF). However, their effect on clinical outcomes, including mortality, ... Full text Link to item Cite

Atrial shunt therapy for heart failure: an update review.

Journal Article Heart Fail Rev · December 2, 2025 Interatrial shunt devices (IASDs) and implant-free strategies have emerged as novel approaches for heart failure (HF) management by mechanically unloading the left atrium (LA) to reduce left atrial pressure (LAP), a key driver of pulmonary congestion and e ... Full text Link to item Cite

Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis.

Journal Article J Thromb Thrombolysis · October 2025 BACKGROUND: Vitamin K antagonists (VKAs) are the first-line strategy for anticoagulation in patients with left ventricular assist devices (LVADs). Recently, the HeartMate 3 (HM3) LVAD, has shown lower thrombotic complications than previous technologies. Di ... Full text Link to item Cite

PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs

Journal Article Open Heart · August 21, 2025 Background Familial hypercholesterolaemia (FH) is a hereditary disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels, substantially increasing the risk of atherosclerotic cardiovascular disease. Proprotein convertase subtili ... Full text Cite

Clinical and Epidemiological Profile of Heart Failure Patients With Chagas Disease: Insights From the SEPE-HF Registry.

Journal Article Am J Cardiol · August 18, 2025 Chagas cardiomyopathy (Ch-CMP) represents a unique and understudied phenotype of heart failure (HF) in endemic regions, with distinct clinical, electrocardiographic, and therapeutic characteristics compared to non-Chagas HF. In this retrospective cohort of ... Full text Link to item Cite

Heart Failure Registry in Santa Cruz de la Sierra, Bolivia. SEPE-HF Registry

Journal Article Revista Argentina De Cardiologia · August 1, 2025 Background: Heart failure is a true pandemic affecting more than 64 million people worldwide. It is essential to know the local reality in order to implement the most appropriate diagnostic and therapeutic actions. We conducted a heart failure registry in ... Full text Cite

Exploring comorbidities, triggers, and etiologies in heart failure. Insights from the SEPE registry subanalysis

Journal Article Rec Cardioclinics · January 1, 2025 Introduction and objectives Heart failure (HF) is a complex clinical syndrome characterized by a high burden of comorbidities and multiple underlying etiologies. This sub-analysis of the SEPE-Registry aimed to characterize the clinical profiles of hospital ... Full text Cite

3D Printing for Left Ventricular Assist Device Exchange: Insights From Real-World Experience.

Journal Article JACC Case Rep · March 6, 2024 Left ventricular assist devices (LVADs) are used in end-stage heart failure. Inadequate positioning of the inflow cannula may necessitate replacement of the LVAD. We present the successful use of a three-dimensional printed model used to optimize surgical ... Full text Open Access Link to item Cite

Dengue Myocarditis: A Case Report and Major Review.

Journal Article Glob Heart · 2023 Dengue is a viral disease transmitted by the bite of a female arthropod, prevalent primarily in tropical and subtropical regions. Its manifestations include asymptomatic infections, dengue fever, and a severe form called hemorrhagic dengue or dengue shock ... Full text Open Access Link to item Cite

Emerging concepts in heart failure management and treatment: focus on vericiguat

Journal Article Drugs in Context · January 1, 2023 The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is dysregulated in patients with heart failure (HF) resulting in myocardial and vascular dysfunction that contributes to its progression. Vericiguat is a no ... Full text Cite

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Journal Article Drugs in Context · January 1, 2023 One of the most relevant and differentiating aspects provided by the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure is the retraction of the historical stepped and vertical pharmacological ... Full text Cite

Emerging concepts in heart failure management and treatment: circulatory support with extracorporeal membrane oxygenation (ECMO)

Journal Article Drugs in Context · January 1, 2023 Circulatory support with extracorporeal membrane oxygenation (ECMO) is being increasingly used in several critical situations but evidence of its impact on outcomes is inconsistent. Understanding of the specific indications and appropriate timing of implan ... Full text Cite

Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy

Journal Article Drugs in Context · January 1, 2023 Tachycardia-induced cardiomyopathy is an entity characterized by reversible dysfunction of the left ventricle, which can be induced by different types of arrhythmia such as atrial fibrillation, atrial flutter, incessant supraventricular tachycardia and ven ... Full text Cite

Emerging concepts in heart failure management and treatment: focus on point-of-care ultrasound in cardiogenic shock

Journal Article Drugs in Context · January 1, 2023 Point-of-care ultrasound (POCUS) plays a strategic role in the diagnostic and therapeutic evaluation of critically ill patients and, especially, in those who are haemodynamically unstable. In this context, POCUS allows a more precise identification of the ... Full text Cite

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.

Journal Article Lancet Respir Med · March 2021 BACKGROUND: Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors (angiotensin-converting enzyme ... Full text Open Access Link to item Cite

First registry of heart failure at the Caja Nacional de Salud Hospital. PRICNASA registry

Journal Article Revista De La Federacion Argentina De Cardiologia · January 1, 2021 Background: Heart failure is a disease that affects millions of people around the world. A chronic phase characterization is important in Latin American countries. It is with this motivation that the authors decided to carry out a registry at hospital leve ... Cite

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Journal Article J Clin Hypertens (Greenwich) · October 2020 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin-converting enzyme 2 (ACE2), which facilitates SA ... Full text Open Access Link to item Cite

Smartphone 12-lead ECG-Exciting but must be handled with care.

Journal Article Am Heart J · August 2020 Full text Open Access Link to item Cite

Heroes, vectors or victims health professionals require all the necessary resources to fight the COVID-19 pandemic

Journal Article Insuficiencia Cardiaca · April 1, 2020 The involvement of SARS-CoV-2 infection in health personnel constitutes a serious problem for controlling the effects of the pandemic. The contagion of health personnel constitutes not only a risk for the professionals who are infected, but also for their ... Cite

Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction.

Journal Article Am Heart J · March 2020 BACKGROUND: The rate-limiting step in STEMI diagnosis often is the availability of a 12-lead electrocardiogram (ECG) and its interpretation. The potential may exist to speed the availability of 12-lead ECG information by using commonly available mobile tec ... Full text Open Access Link to item Cite

Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study.

Journal Article J Electrocardiol · 2018 In patients experiencing an ST-elevation myocardial infarction (STEMI), rapid diagnosis and immediate access to reperfusion therapy leads to optimal clinical outcomes. The rate-limiting step in STEMI diagnosis is the availability and performance of a 12-le ... Full text Open Access Link to item Cite

Unmet goals in the treatment of Acute Myocardial Infarction: Review

Journal Article F1000research · January 1, 2017 Reperfusion therapy decreases myocardium damage during an acute coronary event and consequently mortality. However, there are unmet needs in the treatment of acute myocardial infarction, consequently mortality and heart failure continue to occur in about 1 ... Full text Cite

Editorial

Journal Article Insuficiencia Cardiaca · January 1, 2017 Cite

New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy

Journal Article International Journal of Angiology · December 1, 2016 The new percutaneous Impella CP (Cardiac Power; Abiomed, Inc., Danvers, MA) was designed to provide a higher level of support than Impella 2.5 (Abiomed, Inc.). We present the first documented case of a patient that was transitioned from the Impella 2.5 to ... Full text Cite

Smartphone ECG for evaluation of STEMI: results of the ST LEUIS Pilot Study.

Journal Article J Electrocardiol · 2015 BACKGROUND: 12-lead ECG is a critical component of initial evaluation of cardiac ischemia, but has traditionally been limited to large, dedicated equipment in medical care environments. Smartphones provide a potential alternative platform for the extension ... Full text Open Access Link to item Cite

Prehospital Management of ACUTE STEMI. An International Perspective

Book · 2015 Cardiotext ... Cite

NEW IMPELLA CP (CARDIAC POWER ) DEVICE USED FOR CARDIAC SUPPORT IN PATIENT WITH CARDIOGENIC SHOCK DUE TO NONISCHEMIC CARDIOMYOPATHY.Case Report

Journal Article The International journal of angiology : official publication of the International College of Angiology, Inc · December 2014 Cite

Availability of a baseline Electrocardiogram changes the application of the Sclarovsky-Birnbaum Myocardial Ischemia Grade.

Journal Article J Electrocardiol · 2014 BACKGROUND AND AIMS: The electrocardiogram (ECG) based Sclarovsky-Birnbaum Ischemia Grade may be used to determine the prognosis of patients with ST-elevation myocardial infarction (STEMI). However, application of the method is based on assumption of the b ... Full text Link to item Cite

The Role of Echocardiography in Heart Failure, Part 1

Journal Article Consultant · 2014 Cite

The Role of Echocardiography in Heart Failure, Part 2

Journal Article Consultant · 2014 Cite

An old assist device for a potential new indication in refractory heart failure

Journal Article Revista Argentina De Cardiologia · January 1, 2014 Full text Cite

Percutaneous hemodynamic support (Impella) in patients with advanced heart failure and/or cardiogenic shock not eligible to PROTECT II trial

Journal Article International Journal of Angiology · December 1, 2013 PROTECT I and II trials have tested the efficacy of Impella in patents with high-risk percutaneous coronary intervention (PCI). However, patients with severe hemodynamic instability such as cardiac arrest, ST-segment elevated myocardial infarction (STEMI), ... Full text Cite

The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?

Journal Article Am Heart J · September 2013 Prompt and accurate identification of ST-elevation myocardial infarction (STEMI) in the presence of left bundle-branch block (LBBB) remains difficult. The 2004 STEMI guideline recommended emergent reperfusion therapy to patients with suspected ischemia and ... Full text Open Access Link to item Cite

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Journal Article N Engl J Med · March 28, 2013 BACKGROUND: Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anem ... Full text Link to item Cite

Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.

Journal Article Clin Res Cardiol · January 2013 BACKGROUND: Cell therapy (CTh) is a promising novel therapy for myocardial infarction (MI) and ischemic cardiomyopathy (iCMP). Recognizing adverse events (AE) is important for safety evaluation, harm prevention and may aid in the design of future trials. O ... Full text Link to item Cite

Very Late Development of Coronary Artery Aneurysm with Total Occlusion following Sirolimus-Eluting Stent Implantation.

Journal Article Int J Angiol · December 2012 A 41-year-old African American woman presented with chest pain and was found to have non-ST segment elevation myocardial infarction with a peak cardiac troponin I of 28.5. Elective cardiac catheterization revealed a 70% ostial left anterior descending (LAD ... Full text Link to item Cite

Use of impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest.

Journal Article Int J Angiol · September 2012 Impella (Abiomed, Danvers, MA) is a percutaneously inserted ventricular assist device (VAD). It has been increasingly used in patients with severe heart failure, cardiogenic shock, and high-risk percutaneous intervention (PCI). However, the use and efficac ... Full text Link to item Cite

Percutaneous Hemodynamic support (impella) in patients with advanced heart failure and/or cardiogenic shock not eligible to PROTECT II Trial (Abstract)

Other Journal of Cardiac Failure · August 8, 2012 Cite

Percutaneous Hemodynamic Support (Impella) in Patients With Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial

Journal Article Journal of Cardiac Failure · August 2012 Full text Cite

Chronic Heart Failure is Associated with Elevated Skeletal Muscle Inflammation and Toll-Like Receptor 4 Signaling

Conference FASEB JOURNAL · April 1, 2012 Link to item Cite

Management of Stable Coronary Artery Disease: From COURAGE, FAMEII, to ISCHEMIA

Journal Article Journal of Clinical & Experimental Cardiology · 2012 Full text Cite

Management of arrhythmias in heart failure. What a practicing physician should know in the current times.

Journal Article Cardiol J · 2012 Arrhythmias play a significant role in the mortality and morbidity as well as hospitalizations of patients who carry a diagnosis of congestive heart failure. With improving survival in a world of novel medications and devices, an understanding of the patho ... Full text Link to item Cite

International Congress on Electrocardiology 2011 in Kingston, Ontario, Canada.

Journal Article J Electrocardiol · 2012 Full text Link to item Cite

Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.

Journal Article Ann Thorac Surg · October 2011 BACKGROUND: Highly sensitized (HS) left ventricular assist device (LVAD) patients with high panel-reactive antibody (PRA) levels present a challenge. Alemtuzumab, a potent depleting agent for T and B lymphocytes (months to years), and plasmapheresis, offer ... Full text Link to item Cite

Cardiac allograft vasculopathy: advances in diagnosis.

Journal Article Cardiol Rev · 2011 Cardiac allograft vasculopathy (CAV), characterized by diffuse intimal thickening and luminal narrowing in the arteries of the allograft, is the leading cause of morbidity and mortality in cardiac transplant recipients. Many transplant centers perform rout ... Full text Link to item Cite

From theory to practice: implementation of pre-hospital electrocardiogram transmission in ST-elevation myocardial infarction - a multicenter experience.

Journal Article J Invasive Cardiol · November 2010 BACKGROUND: Percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI) reduces morbidity and mortality if performed rapidly. We examined whether timely intervention in myocardial perfusion times achieved at NorthEast Medical Center ( ... Link to item Cite

Review article: the new concept of interventional heart failure therapy--part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support.

Journal Article J Cardiovasc Pharmacol Ther · June 2010 Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target ... Full text Link to item Cite

Cardiac calcitonin gene-related peptide and left ventricular hypertrophy in the cardiac allograft.

Journal Article J Heart Lung Transplant · April 2010 Full text Link to item Cite

487: Alemtuzumab, a Promising Tool in the Rescue Armamentarium for Refractory Allograft Dysfunction with Cardiogenic Shock: Experience from a Single-Institution

Conference The Journal of Heart and Lung Transplantation · February 2010 Full text Cite

175: Highly Sensitized LVAD Patients Can Be Safely Transplanted with Non-Crossmatched Hearts Using Plasmapheresis and Alemtuzumab: A Contemporaneous Case-Control Series

Conference The Journal of Heart and Lung Transplantation · February 2010 Full text Cite

Hypothyroidism and renal function in patients with systolic heart failure.

Journal Article Tex Heart Inst J · 2010 The extent to which hypothyroidism affects renal function in patients with heart failure remains incompletely explored, despite the known adverse prognostic implications of renal dysfunction in these patients.In a pilot retrospective study, we evaluated 75 ... Link to item Cite

Is Thoracic Impedance Cardiography ready to replace invasive techniques for measuring cardiac indices? (Abstract)

Other Journal of Cardiac Failure · 2010 Cite

Diastolic dysfunction and COPD exacerbation.

Journal Article Postgrad Med · July 2009 INTRODUCTION: Chronic obstructive pulmonary disease (COPD) exacerbation is a frequent cause of hospital admissions. In one-third of patients, exacerbations have no known cause. We studied whether the presence of diastolic dysfunction (DD) in this subgroup ... Full text Link to item Cite

Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem.

Journal Article Curr Cardiol Rev · May 2009 HIV/AIDS (Human immunodeficiency virus/ Acquired immuno deficiency syndrome) is a growing global problem, in terms of its incidence and mortality. Patients with HIV/AIDS are living much longer with HAART (Highly active antiretroviral therapy) therapy so mu ... Full text Link to item Cite

Management of Hypertension in Heart failure. Revisiting the Guidelines

Journal Article Expert Review of Cardiovascular Therapy · April 7, 2009 Cite

Management of hypertension in chronic heart failure.

Journal Article Expert Rev Cardiovasc Ther · April 2009 Chronic heart failure (CHF) is associated with frequent hospitalizations and high mortality. It affects more than 5 million individuals in the USA, and another 660,000 new cases are diagnosed each year; overall, heart failure (HF) now accounts for 7% of al ... Full text Link to item Cite

Atlas of Advanced ECG Interpretation

Book · 2009 Cite

Calcitonin Gene-Related Peptide as a Potential Marker of Compensation in Patients with Acute Heart Failure Exacerbations (Abstract)

Other Journal of Cardiac Failure · 2009 Cite

Overcoming barriers to developing seamless ST-segment elevation myocardial infarction care systems in the United States: recommendations from a comprehensive Prehospital 12-lead Electrocardiogram Working Group.

Journal Article J Electrocardiol · 2009 BACKGROUND: Reducing time to reperfusion treatment for patients with ST-segment elevation myocardial infarction (STEMI) improves patient outcomes. Few medical systems consistently meet current benchmarks regarding timely access to treatment. Studies have w ... Full text Link to item Cite

Diastolic Dysfunction (DD) Is a Useful Marker to Risk Stratify Patients with Frequent COPD Exacerbations and Normal Left Ventricular Ejection Fraction (LVEF)

Journal Article Journal of Cardiac Failure · August 2008 Full text Cite

Diastolic Dysfunction (DD) Is a Useful Marker to Risk Stratify Patients with Frequent COPD Exacerbations and Normal Left Ventricular Ejection Fraction (LVEF) (Abstract)

Other Journal of Cardiac Failure · 2008 12th Annual Scientific meeting Heart Failure Society of America (September 21-24, 2008) Toronto, ON, Canada. ... Cite

Why are Large Clinical research Databases Needed?

Chapter · October 2007 Cite

Effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis: A meta-analysis of published studies

Journal Article American Journal of Cardiology · September 1, 2007 Cite

Non Ischemic ST Segment Elevation: a Frequent Finding in General Hospital Population (Abstract)

Other Computers in cardiology · September 2007 Cite

Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis.

Journal Article Am J Cardiol · September 1, 2007 Myonecrosis, manifested by an increase in cardiac markers, may occur in up to 50% of patients undergoing elective percutaneous coronary intervention (PCI). The degree of periprocedural myonecrosis, measured by the peak creatine kinase-MB fraction, has been ... Full text Link to item Cite

Time to reperfusion in acute myocardial infarction. It is time to reduce it!

Journal Article J Electrocardiol · July 2007 BACKGROUND AND OBJECTIVES: Mortality from ST-segment elevation myocardial infarction remains high, with most deaths occurring before hospital admission. Despite effective pre- and in-hospital reperfusion strategies becoming standard over the past 2 decades ... Full text Link to item Cite

Usefulness of ST depression with T-wave inversion in leads V(4) to V(6) for predicting one-year mortality in non-ST-elevation acute coronary syndrome (from the Electrocardiographic Analysis of the Global Use of Strategies to Open Occluded Coronary Arteries IIB Trial).

Journal Article Am J Cardiol · April 1, 2007 ST-segment depression (ST-D) on the admission electrocardiogram of patients with non-ST-elevation acute coronary syndromes (NSTEACSs) is associated with higher mortality. However, few studies have evaluated the effect of location of ST-D and T-wave polarit ... Full text Link to item Cite

Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction.

Journal Article J Electrocardiol · January 2007 OBJECTIVES: ST resolution (STR) is a surrogate marker of myocardial tissue reperfusion and a predictor of outcome after primary percutaneous coronary intervention (pPCI) for ST-elevation myocardial infarction (STEMI). Terminal QRS distortion (grade 3 ische ... Full text Link to item Cite

Time to Reperfusion in Acute Myocardial Infarction. It is time to Reduce It. The Potential Key role of the ECG wireless transmission

Journal Article Journal of Electrocardiology · 2007 Cite

Renal function and thyroid status in heart failure (Abstract)

Other Journal of Cardiac Failure · 2007 The 11th Annual Scientific meeting of the Heart Failure Society ... Cite

Calcitonin gene-related peptide as a neurohormonal marker in patients with Decompensated Heart Failure (Abstract)

Other Circulation · 2007 Cite

Wireless electrocardiogram in early diagnosis and triaging of ST-elevation myocardial infarction: The TIME Study

Journal Article Journal of Electrocardiology · January 1, 2007 Full text Cite

Denying reperfusion or falsely declaring emergency: the dilemma posed by ST-segment elevation.

Journal Article J Electrocardiol · October 2006 Full text Link to item Cite

Electrocardiographic markers of reperfusion in ST-elevation myocardial infarction.

Journal Article Cardiol Clin · August 2006 The outcome of patients who fail to reperfuse with thrombolytic therapy or percutaneous coronary intervention (PCI) for ST-elevation acute myocardial infarction (STEMI) may be improved with additional pharmacologic and mechanical interventions such as resc ... Full text Link to item Cite

Electrocardiographic diagnosis of ST-elevation myocardial infarction.

Journal Article Cardiol Clin · August 2006 The ECG is an essential part of the initial evaluation of patients who have chest pain, especially in the immediate decision-making process in patients who have ST-elevation myocardial infarction. This article reviews and summarizes the current information ... Full text Link to item Cite

The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience.

Journal Article Am Heart J · August 2006 BACKGROUND: Prior research suggests that patients may be entered into clinical trials with different electrocardiographic (ECG) findings than specified by study protocol criteria; the extent and impact of this variability in a large-scale trial have not be ... Full text Link to item Cite

Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction.

Journal Article J Electrocardiol · July 2006 We describe a patient who presented with abdominal pain radiating to the chest and ST elevation in the precordial leads, mimicking acute myocardial infarction. Urgent coronary angiography revealed normal coronary arteries and his serum troponin has not inc ... Full text Link to item Cite

Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.

Journal Article Expert Opin Investig Drugs · May 2006 The neurohormone arginine vasopressin plays a significant role in the regulation of volume homeostasis, which is mediated via vasopressin type 2 (V2) receptors in the collecting tubules of the kidney. Diseases that are accompanied by abnormal volume homeos ... Full text Link to item Cite

Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade.

Journal Article Am Heart J · January 2006 BACKGROUND: The acute decompensated heart failure (ADHF) is not as well characterized as the chronic phase, particularly in Latin American countries. Thus, the aim of this overview was to describe the clinical profile, treatment, and inhospital course of A ... Full text Link to item Cite

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial.

Journal Article Am Heart J · October 2005 BACKGROUND: Noninvasive methods are needed to evaluate reperfusion success in patients with acute myocardial infarction (MI). The AMISTAD trial was analyzed to compare MI size and myocardial salvage determined by electrocardiogram (ECG) with technetium Tc ... Full text Link to item Cite

Have we made progress in reducing time to reperfusion in the management of acute myocardial infarction? A last decade overview. The potential key role of wireless electrocardiographic transmission.

Journal Article J Electrocardiol · October 2005 Full text Link to item Cite

Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias.

Journal Article J Cardiovasc Pharmacol Ther · September 2005 BACKGROUND: Tolvaptan, a nonpeptide selective vasopressin receptor (V2) antagonist, is in development for the treatment of congestive heart failure and hyponatremia. Tolvaptan is primarily metabolized via CYP3A4. This study was conducted to determine the e ... Full text Link to item Cite

Overview of Acute Decompensated Heart Failure in Argentina: Lessons Learned from Five Registries during the Last Decade

Journal Article Journal of Cardiac Failure · August 2005 Full text Cite

Overview of acute decompensated heart failure in Argentina: Lessons learned from five registries during the last decade (Abstract)

Other Journal of Cardiac Failure · 2005 Cite

Prognostic value of admission troponin T in patients with acute decompensated heart failure (Abstract)

Other Revista Argentia de Cardiologia (Argentine Journal of Cardiology) · 2005 Cite

An academic ECG core lab perspective of the FDA initiative for digital ECG capture and data management in large-scale clinical trials

Journal Article Drug Information Journal · 2005 Maximal utility of accessible data is attractive to all partners in clinical research, whether it directly improves patient care or more accurately allows identification of the safety and efficacy of a new drug or procedure. The Food and Drug Administratio ... Cite

Have we made progress in reducing time to reperfusion in the management of acute myocardial infarction? A last decade overview - The potential key role of wireless electrocardiographic transmission

Journal Article JOURNAL OF ELECTROCARDIOLOGY · 2005 Cite

Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy.

Journal Article Am Heart J · November 2004 BACKGROUND: Current methods for risk stratification after acute myocardial infarction (MI) include several noninvasive studies. In this cost-containment era, the development of low-cost means should be encouraged. We assessed the ability of an electrocardi ... Full text Link to item Cite

Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification.

Journal Article Circulation · October 19, 2004 BACKGROUND: The progression of chronic heart failure (CHF) is related to ongoing myocyte loss, which can be detected by cardiac troponin T (cTnT). We examined the prevalence and prognostic value of increased cTnT concentrations in serial blood specimens fr ... Full text Link to item Cite

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Journal Article JAMA · April 28, 2004 CONTEXT: Nearly 1 million hospitalizations for chronic heart failure occur yearly in the United States, with most related to worsening systemic congestion. Diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and ... Full text Link to item Cite

1163-109 Ongoing myocardial damage in severe heart failure: Prognostic usefulness of cardiac troponin T monitoring to identifying high-risk patients

Journal Article Journal of the American College of Cardiology · March 2004 Full text Cite

Aborted infarction: the ultimate myocardial salvage.

Journal Article Am Heart J · March 2004 Full text Link to item Cite

Acute and Chronic Therapeutic Impact of a Vasopressin 2 Antagonist (Tolvaptan) in Congestive Heart Failure (ACTIV in CHF): A multicenter, randomized trial in patients hospitalized with worsening heart failure

Journal Article JAMA · 2004 Cite

Ongoing myocardial damage in severe heart failure: prognostic usefulness of cardiac troponin T monitoring to identifying high risk patients (Abstract)

Other Journal of the American College of Cardiology · 2004 Cite

Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF Trial

Other Journal of the American College of Cardiology · 2004 Cite

Erratum: Aborted infarction: The ultimate myocardial salvage (American Heart Journal (2004) 147 (390-394))

Journal Article American Heart Journal · January 1, 2004 Full text Cite

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.

Journal Article Am Heart J · February 2003 Full text Link to item Cite

but not high-sensitivity C-reactive protein, predicts outcomes in patients hospitalized with acute descompensated heart failure (Abstract)

Other Journal of Cardiology · 2003 Cite

Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis.

Journal Article Cardiology · 2002 We assessed the relation between baseline electrocardiographic ischemia grades and initial myocardial area at risk (AR) and final infarct size (IS) in 49 patients who had undergone (99m)Tc sestamibi single-photon emission computed tomography before and 6 + ... Full text Link to item Cite

Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram.

Journal Article Am J Cardiol · October 15, 2001 We investigated the impact of primary angioplasty compared with thrombolysis in 894 patients with ST elevation acute myocardial infarction and electrocardiographic grades II and III ischemia on enrollment. Patients were divided into 2 groups based on the e ... Full text Link to item Cite

Grade 3 ischemia on presentation in acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolytic therapy (Abstract)

Other Journal of the American College of Cardiology · 2001 Cite

Standards for the function of an academic 12-lead electrocardiographic core laboratory.

Journal Article J Electrocardiol · January 2001 An academic 12-lead electrocardiogram (ECG) core laboratory aims to provide the highest possible quality ECG recording, measurement, and storage to aid clinicians in research into important cardiovascular outcomes and to maximize the credibility of scienti ... Full text Link to item Cite

Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate.

Journal Article Am Heart J · September 2000 BACKGROUND: Recent studies have reported that negative T waves in the setting of acute coronary events are associated with Thrombolysis In Myocardial Infarction flow grade 3 in the infarct-related artery and with improved parameters of ventricular function ... Full text Link to item Cite

Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial).

Journal Article Am J Cardiol · July 1, 2000 Previous reports indicate that patients who do not develop Q waves after thrombolytic therapy are a different population with a better long-term survival than those who do develop Q waves. However, the use of resources, quality of life, and health status o ... Full text Link to item Cite

The correlation between presenting ST-segment depression and the final size of acute myocardial infarcts in patients with acute coronary syndromes.

Journal Article J Electrocardiol · 2000 The use of reperfusion therapy in patients with ST elevation acute coronary syndromes had been established. However, reperfusion therapy is usually considered contra-indicated in those with ST depression, despite the knowledge that regional posterior infar ... Full text Link to item Cite

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.

Journal Article J Am Coll Cardiol · November 15, 1999 OBJECTIVES: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial was designed to test the hypothesis that adenosine as an adjunct to thrombolysis would reduce myocardial infarct size. BACKGROUND: Reperfusion therapy for acute myocardial infar ... Full text Link to item Cite

The comparison of an electrocardiographic salvage index with spect sestamibi scintigraphy in patients with acute myocardial infarction: An AMISTAD substudy.

Journal Article Journal of Electrocardiology · 1999 Cite

The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine.

Journal Article J Electrocardiol · 1999 Full text Link to item Cite

ECG subanalyses in clinical trials: an investigator's perspective.

Journal Article J Electrocardiol · 1999 Full text Link to item Cite

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

Journal Article Circulation · June 23, 1998 BACKGROUND: Unstable angina and non-Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and ... Full text Link to item Cite

Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.

Journal Article Circulation · February 10, 1998 BACKGROUND: Although the stratification of patients with myocardial infarction into ECG subsets based on the presence or absence of new Q waves has important clinical and prognostic utility, systematic evaluation of the impact of thrombolytic therapy on th ... Full text Link to item Cite